EUVIMEDEUVIMED entdecken
Crossref

Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug

Jeanne Lenzer, Shannon Brownlee

BMJ · 2024

DOI: 10.1136/bmj.q2010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMJ, 2024. Verfasst von Jeanne Lenzer und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Alzheimer Disease, Conflict of Interest, United States Food and Drug Administration, Drug Approval. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseConflict of InterestUnited States Food and Drug AdministrationDrug ApprovalHumansUnited StatesAntibodies, Monoclonal, HumanizedDrug Industry

Substanzen

Antibodies, Monoclonal, Humanizedaducanumabdonanemab

Zitieren

APA

Lenzer, J., & Brownlee, S. (2024). Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug. BMJ. https://doi.org/10.1136/bmj.q2010

Vancouver

Lenzer J, Brownlee S. Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug. BMJ. 2024. doi:10.1136/bmj.q2010

BibTeX
@article{Lenzer2024,
  author = {Lenzer, Jeanne and Brownlee, Shannon},
  title = {Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug},
  journal = {BMJ},
  year = {2024},
  doi = {10.1136/bmj.q2010}
}
Kostenlos starten →